Fresenius Kabi Launches Denosumab Biosimilars in Canada

Conexxence and Bomyntra, both approved by Health Canada in April 2026, are now available in the Canadian market.

Updated on Nov. 16, 2026 in Healthcare

Bold flat-color editorial illustration of a single unlabeled syringe and two amber vials against a navy field, evoking a new medical product entering the Canadian market.
Fresenius Kabi launched two denosumab biosimilars, Conexxence and Bomyntra, in Canada after Health Canada approved both products in April 2026. AI Illustration. Upload story photo >

Fresenius Kabi Canada has launched Conexxence and Bomyntra, two denosumab biosimilars, in Canada. Health Canada approved both products in April 2026, with Conexxence matching the indications of the reference product Prolia and Bomyntra matching those of Xgeva.

Why it matters

The launch adds two biosimilar options for denosumab, a treatment used for osteoporosis and for skeletal-related complications in patients with bone metastases or multiple myeloma. Both products are administered by subcutaneous injection, and Fresenius Kabi says it is the first and only biosimilar company to offer a ready-to-use pre-filled syringe for oncology indications of denosumab in Canada.

Conexxence is supplied at 60 mg/mL and Bomyntra at 120 mg/1.7 mL, both approved by Health Canada in April 2026 against the reference products Prolia and Xgeva. Pricing, reimbursement coverage and early uptake in Canada were not disclosed in the announcement.

The players

Fresenius Kabi

Fresenius Kabi is a global healthcare company headquartered in Bad Homburg, Germany, that produces generic and biosimilar medicines and infusion and clinical nutrition products. It has a workforce of about 41,000 employees and operates in around 100 countries.

The details

Conexxence was developed through analytical, non-clinical and clinical studies, including a Phase 1 pharmacokinetic/pharmacodynamic trial in healthy volunteers and a Phase 3 trial known as LUMIADE-3. Conexxence is approved for osteoporosis treatment in postmenopausal women and in men at increased risk of fracture, and for treatment-induced bone loss.

Timeline

  1. April 2026: Health Canada approved Conexxence and Bomyntra.

  2. November 16, 2026: Fresenius Kabi Canada announced the Canadian launch of both products.

Market Landscape

The approvals follow the biosimilar pathway, under which Health Canada assessed Conexxence and Bomyntra against the established denosumab products Prolia and Xgeva. Fresenius Kabi already markets Idacio, Tyenne and Otulfi in Canada, so these launches add to an existing biosimilar portfolio rather than entering the category for the first time.

For Canadians treated with denosumab, the launch adds biosimilar options that carry the same approved indications as Prolia and Xgeva. Whether either product lowers out-of-pocket costs will depend on provincial coverage decisions that the announcement does not address.

The takeaway

Patients and prescribers in Canada now have additional denosumab biosimilar options with approved indications matching their reference products. Anyone considering a switch should confirm coverage and dosing with their care provider or pharmacist.

Further reading

For more on how drug pricing and access shape the sector, explore Healthcare coverage across Canada.

More information

Read the Conexxence Health Canada product description for the approved product details.

Source note: This article includes information reported by Firstwordpharma.